FDA Grants EUA for Bimectin to Combat New World Screwworm in Cattle

The U.S. Food and Drug Administration (FDA) has granted an Emergency Use Authorization (EUA) for Bimectin (ivermectin) injection, aimed at preventing New World screwworm (NWS) infestations in cattle. Effective immediately as of August 2026, this action expands treatment access beyond a single manufacturer, which is crucial for agricultural biosecurity and food safety in the United States.

This authorization aligns with ongoing efforts to secure American agriculture from threats like the New World screwworm—a pest notorious for its capacity to inflict severe damage to livestock. The broad availability of this critical veterinary drug will serve to enhance livestock health and mitigate the economic impacts of pest infestations. Timothy Schell, Ph.D., director of the FDA’s Center for Veterinary Medicine, remarked, “This authorization reflects the FDA’s commitment to expanding generic drug options. By authorizing both generic and pioneer products, the Agency ensures producers aren’t dependent on a single manufacturer.” This underscores the importance of having multiple suppliers to ensure stable drug availability during pest-related emergencies.

Bimectin injection, which has previously been approved for various parasitic treatments in cattle, can now be used specifically within the framework of the EUA for treating NWS infestations. Farmers will especially appreciate that this generic option facilitates competitive procurement scenarios, as agencies can now access this solution from various suppliers. Moreover, the drug is available over the counter, empowering cattle producers to manage infestations effectively while remaining compliant with FDA regulations.

Procurement professionals should be cognizant that while the EUA enables federal and state agencies to incorporate this generic ivermectin injection into their purchasing plans, there remain strict usage restrictions. Cattle producers must adhere to specific guidelines—such as not using the drug on lactating dairy cows or calves destined for veal—to maintain food safety and avoid regulatory penalties. The use guidelines dictate a 35-day slaughter withdrawal time to ensure the safety of the food supply. These crucial compliance factors should be an integral aspect of procurement contracts pertaining to veterinary pharmaceuticals.

In light of these developments, agricultural and veterinary health agencies are encouraged to revisit their procurement strategies and incorporate this newly authorized drug into their plans. This proactive approach can further enhance preparedness against possible screwworm outbreaks, which, if left unaddressed, could lead to devastating economic impacts on the cattle industry.

The implications of this EUA extend beyond immediate agricultural safety; they represent a strategic adaptation within regulatory frameworks to ensure a timely response to emerging threats in livestock health. As stakeholders in the agricultural sector embrace this new generic option, they are also called to enhance their understanding of regulatory compliance, particularly given the FDA's vigilant stance on food safety standards.

This move may spur more investment in veterinary pharmaceuticals targeting other pests and diseases affecting livestock, thus fostering a resilient supply chain for agricultural producers across the nation.

• The FDA has issued an Emergency Use Authorization for Bimectin (ivermectin) effective August 2026.
• Bimectin is specifically for preventing New World screwworm infestations in cattle.
• This EUA allows for broader access to generic ivermectin injections, ensuring supply stability.
• Contractors in veterinary pharmaceuticals may see increased procurement opportunities.
• Compliance with FDA restrictions is crucial to maintain food safety in related contracts.
• Updated procurement plans should include Bimectin to strengthen readiness against future outbreaks.
• The 35-day slaughter withdrawal time is mandatory for food safety following drug administration.
• Agencies should actively seek new suppliers of generic ivermectin to diversify procurement sources.
• Bimectin injection was previously approved for other parasitic treatments, enhancing its utility for cattle producers.